Overview

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Status:
Active, not recruiting

Trial end date:
2022-10-28

Target enrollment:

Participant gender:

Summary

This study evaluates the safety of abemaciclib in combination therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, LY3023414 plus fulvestrant, pertuzumab plus trastuzumab with loperamide, or ongoing endocrine therapy) for breast cancer that has spread to other parts of the body.

Phase:

Phase 1

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Anastrozole
Estradiol
Everolimus
Exemestane
Fulvestrant
Letrozole
Loperamide
Pertuzumab
Sirolimus
Tamoxifen
Trastuzumab